Ipsen successfully issues inaugural €300 million 7-year Notes
Ipsen, a global specialty-driven pharmaceutical group, announced today the successful issue of its inaugural unsecured 7-year Notes for a total of €300 million.
These Notes mature on June 16, 2023 and pay interest at an annual rate of 1.875%. Application has been made for the Notes to be admitted to trading on the regulated market of Euronext Paris.
Ipsen has been able to take advantage of the current market environment to raise long-term financing at attractive conditions. The transaction was well received by a diversified investor base and was more than 4 times over-subscribed, demonstrating the market’s confidence in Ipsen’s long-term business model.
The purpose of this issue is to diversify and extend the maturity of Ipsen’s financial resources and to support its investment and business development strategy.
BNP Paribas, HSBC Bank plc, and Société Générale were Global Coordinators and Joint Lead Managers. Crédit Agricole Corporate and Investment Bank and Natixis also acted as Joint Lead Managers.
|About the Notes:
Issuer: Ipsen S.A.
Amount: €300 million
Maturity: 7 years
Market: Euronext Paris (Regulated Market)